Agency Forms Undergoing Paperwork Reduction Act Review

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30 DAY-26]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a

list of information collection requests under review by the Office of

Management and Budget (OMB) in compliance with the Paperwork Reduction

Act (44 U.S.C. Chapter 35). To request a copy of these requests, call

the CDC Reports Clearance Office on (404) 639-7090. Send written

comments to CDC, Desk Officer; Human Resources and Housing Branch, New

Executive Office Building, Room 10235; Washington, DC 20503. Written

comments should be received within 30 days of this notice.

The following requests have been submitted for review since the

last publication date on January 16, 1997.

Proposed Project

Studies of Immunotoxicity in Occupational Groups--(0920-0333)--

Reinstatement--A number of chemicals to which U.S. workers are

potentially exposed, including metals such as lead and beryllium and

solvents such as carbon tetrachloride, have been found to be

immunotoxic in experimental animals. There is little data on

immunosuppression, hypersensitivity or autoimmune disease in workers

exposed to chemicals that are immunotoxic in experimental animals.

NIOSH has undertaken a coordinated series of studies to focus on

immune-system effects related to specific chemical exposures in the

workplace. In the previous three years, NIOSH conducted studies of lead

and egg protein exposed workers.

In this reinstatement of the program, it is anticipated that up to

six additional research studies will be conducted under this program.

Examples of chemicals for which studies are being considered are latex,

silica, and solvents. In most of these studies, the immune function of

a group of workers exposed to the chemical of interest, and not exposed

to any other known or potential immunotoxins, will be compared to the

immune function in a group of individuals with no occupational exposure

to known or suspected immunotoxins. In some studies, the immune

function in a group of individuals will be compared before and after

they have exposure to the potential immunotoxin. The primary

information collected will be data on the level of exposure to the

potential immunotoxin (as measured in the air in the breathing zone of

the respondent, and/or in the respondent's blood or urine) and data on

specific markers of the status of the immune system from blood or

saliva samples provided by the subjects. The questionnaire data will be

directed at demographic, lifestyle, and medical factors (other than the

exposure or condition of interest) which may influence the function of

the immune system. In selected studies, the questionnaire will be used

to assess the presence of respiratory symptoms, dermatologic conditions

and/or reproductive effects, if the literature indicates a potential

relationship to these health problems. Study populations will be

identified through telephone contact and follow-up site visits (if

needed) with workplace facilities that use the chemical of interest.

The total annual burden is 1607.

----------------------------------------------------------------------------------------------------------------

Avg.

No. of burden/

Respondent (form) No. of responses/ response Total burden

respondents respondent (in (in hrs.)

hrs.)

----------------------------------------------------------------------------------------------------------------

Interview and blood collection.............................. 600 1 1 600

Additional interview module (respiratory, dermatologic, or

reproductive).............................................. 600 1 .5 300

Peak flow measurement (hypersensitivity studies only)....... 200 28 .08 467

Allergy skin tests (hypersensitivity studies only).......... 200 1 1 200

Company interview........................................... 40 1 1 40

----------------------------------------------------------------------------------------------------------------

Dated: January 15, 1997.

William G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers

for Disease Control and Prevention (CDC).

[FR Doc. 97-1475 Filed 1-21-97; 8:45 am]

BILLING CODE 4163-18-P